Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.82
-2.8%
$23.55
$17.24
$28.75
$17.85B0.931.38 million shs1.48 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$80.47
-2.1%
$78.68
$55.53
$113.51
$5.93B1.29391,814 shs405,266 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$18.94
+1.8%
$25.45
$15.55
$36.91
$13.82B-1.024.37 million shs6.51 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$19.96
+0.4%
$17.31
$12.47
$22.80
$22.81B0.729.88 million shs9.14 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-2.76%+1.02%+22.72%+21.91%+3.30%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-2.13%-0.52%+2.85%+2.85%-6.03%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.83%-27.10%-29.48%-4.25%-16.56%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.35%+5.41%+15.98%+17.43%+11.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.82
-2.8%
$23.55
$17.24
$28.75
$17.85B0.931.38 million shs1.48 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$80.47
-2.1%
$78.68
$55.53
$113.51
$5.93B1.29391,814 shs405,266 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$18.94
+1.8%
$25.45
$15.55
$36.91
$13.82B-1.024.37 million shs6.51 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$19.96
+0.4%
$17.31
$12.47
$22.80
$22.81B0.729.88 million shs9.14 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-2.76%+1.02%+22.72%+21.91%+3.30%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-2.13%-0.52%+2.85%+2.85%-6.03%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.83%-27.10%-29.48%-4.25%-16.56%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.35%+5.41%+15.98%+17.43%+11.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.70
Moderate Buy$39.2541.09% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.08
Buy$120.9150.25% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.65
Moderate Buy$33.7978.38% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.25
Buy$24.7123.82% Upside

Current Analyst Ratings Breakdown

Latest NUVL, TEVA, SMMT, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$115.00
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
9/4/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$122.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$40.00
9/2/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$105.00
9/2/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/27/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $50.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$21.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.26B5.47$1.47 per share18.87$8.04 per share3.46
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$14.99 per shareN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K20,099.40N/AN/A$0.53 per share35.74
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.38$3.38 per share5.91$4.74 per share4.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.9913.9815.631.6737.53%21.03%16.98%11/6/2025 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$0.16N/A7.591.16-0.95%46.10%7.18%11/5/2025 (Estimated)

Latest NUVL, TEVA, SMMT, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/7/2025Q2 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million
8/7/2025Q2 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.27-$1.31-$0.04-$1.39N/AN/A
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64$0.66+$0.02$0.24$4.34 billion$4.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
6.22
6.20
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
13.57
13.57
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.45
1.06
0.77

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.59 million631.71 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4072.11 million64.75 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable

Recent News About These Companies

Zacks Research Has Pessimistic Outlook of TEVA Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$27.82 -0.79 (-2.76%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$27.82 0.00 (0.00%)
As of 09/12/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$80.47 -1.75 (-2.13%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$80.50 +0.03 (+0.04%)
As of 09/12/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$18.94 +0.34 (+1.83%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$18.92 -0.02 (-0.11%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$19.96 +0.07 (+0.35%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$19.93 -0.03 (-0.13%)
As of 09/12/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.